Loading patent…
AssigneeMabylon AG
InventorsNatascha WUILLEMIN, Dimitri BIELI, Niccolò PENGO, Rahel SCHEIBLING, Chiara ARENA, Tiziana SONATI, Alcide BARBERIS, Pascal GASSER
Estimating the term…
The present invention provides antibodies binding to peanut allergens, in particular to Ara h 2 and Ara h 3 or Ara h 6. The present invention also provides compositions and kits comprising distinct antibodies binding to distinct, non-overlapping epitopes of Ara h 2 and multispecific antibodies binding to distinct, non-overlapping epitopes of Ara h 2. In addition, the present invention also relates to the use of such antibodies, compositions and kits, e.g. for preventing or treating peanut allergy.
An antibody, or an antigen-binding fragment thereof, which binds specifically to Ara h 2 (Arachis hypogaea allergen 2).
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a CDRH1 according to SEQ ID NO:
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH having at least 70% identity to any one of SEQ ID NOs 7, 44 and 45;
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, comprises a VH according to any one of SEQ ID NOs 7, 44 and 45;
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the CDRs or the variable regions of the antibody, or the antigen-binding fragment thereof, are human or are derived from human CDR or variable region sequences.
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a human antibody.
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a monoclonal antibody.
The antibody according to any one according to the previous claims, wherein the antibody comprises an Fc moiety.
The antibody according to any one of the previous claims, wherein the antibody is of the IgG or IgA type.
The antibody according to any one according to the previous claims, wherein the variable regions or the CDRs are derived from an IgE antibody and grafted in a scaffold of an IgG or IgA antibody.
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is purified.
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a single-chain antibody.
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims, wherein the antibody, or the antigen-binding fragment thereof, is a multispecific antibody or a multispecific antigen-binding fragment.
A multispecific antibody, or a multispecific antigen-binding fragment, which binds to distinct, non-overlapping epitopes of Ara h 2, wherein the antibody, or the antigen-binding fragment, comprises at least two of the following:
The antibody, or an antigen-binding fragment thereof, according to any one of the previous claims for use as a medicament.
A composition comprising at least three distinct antibodies, or antigen-binding fragments thereof, wherein the three distinct antibodies or antigen-binding fragments bind to distinct, non-overlapping epitopes of Ara h 2, wherein the composition comprises at least three of the following:
A kit comprising at least three distinct antibodies, or antigen-binding fragments thereof, wherein the three distinct antibodies or antigen-binding fragments bind to distinct, non-overlapping epitopes of Ara h 2, wherein the kit comprises at least three of the following:
Dependencies are inferred from the claim text.